Serum salusin-α and salusin-β levels in patients with Behcet's disease

Eur J Dermatol. 2014 Sep-Oct;24(5):577-82. doi: 10.1684/ejd.2014.2397.

Abstract

Background: Behcet's disease (BD) is a chronic, relapsing, systemic vasculitis of unknown etiology. There is an increased predisposition to insulin resistance and metabolic syndrome (MetS) in BD patients.

Objective: The aim of this study was to determine serum salusin-α and salusin-β levels in BD patients and healthy controls and to investigate their association with MetS.

Patients and methods: Twenty-five BD patients and 25 healthy controls were included in the study. Salusin-α and salusin-β levels were measured in blood samples using ELISA. In addition, BD patients and healthy controls were evaluated in terms of MetS.

Results: The mean serum salusin-α level in BD patients was significantly lower compared to healthy controls (p = 0.03), whereas the mean serum salusin-β level in BD patients was significantly higher compared to healthy controls (p = 0.03). The mean serum salusin-α level was significantly lower in BD patients with MetS compared to BD patients without MetS (p = 0.04).

Conclusions: Serum salusin-α level (an anti-atherogenic molecule) was lower, while serum salusin-β level (a pro-atherogenic molecule) was higher in BD patients. We consider that the decrease in salusin-α and the increase in salusin-β levels contribute to the development of MetS.

Keywords: Behcet's Disease; insulin resistance; metabolic syndrome; salusin-α; salusin-β.

MeSH terms

  • Adult
  • Behcet Syndrome / blood*
  • Behcet Syndrome / complications
  • Case-Control Studies
  • Female
  • Humans
  • Insulin Resistance
  • Intercellular Signaling Peptides and Proteins / blood*
  • Male
  • Metabolic Syndrome / blood*
  • Metabolic Syndrome / complications
  • Sex Factors
  • Young Adult

Substances

  • Intercellular Signaling Peptides and Proteins
  • TOR2A protein, human